SA
Sign upLog In
CVAC

CureVac N.V. is a biotechnology company focused on developing mRNA-based therapies and vaccines, with a particular emphasis on oncology and infectious diseases. Its proprietary mRNA technology platform differentiates it in the competitive landscape, particularly in Europe and North America, where it has established partnerships with major pharmaceutical companies.

HealthcareBiotechnologyhigh - CureVac benefits from high gross margins due to the scalable nature of its mRNA technology, allowing for significant operating leverage as revenue increases.

Business Overview

01mRNA vaccine development partnerships (estimated 60% of total revenue)
02Therapeutic mRNA product sales (estimated 30% of total revenue)
03Research grants and collaborations (estimated 10% of total revenue)

CureVac generates revenue primarily through partnerships with large pharmaceutical companies for the development of mRNA vaccines and therapies. Its competitive advantages include a strong intellectual property portfolio and advanced delivery technologies that enhance the efficacy of mRNA products.

What Moves the Stock

Advancements in mRNA vaccine efficacy and safety data

New partnership announcements with major pharmaceutical companies

Regulatory approvals for pipeline products

Market adoption rates of existing mRNA therapies

Watch on Earnings
Revenue growth rateGross margin percentagePartnership deal value

Risk Factors

Regulatory changes impacting mRNA technology approvals

Technological disruption from competing biotech firms

Emergence of new mRNA competitors with superior technology

Potential for large pharmaceutical companies to develop in-house mRNA capabilities

Low liquidity risk due to high current ratio of 3.70

Potential risks associated with reliance on grant funding

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The biotechnology sector is somewhat insulated from economic downturns, but funding for research and development can be affected by overall economic conditions.

Interest Rates

CureVac is less sensitive to interest rates due to its low debt levels (Debt/Equity of 0.04), but higher rates could impact the valuation multiples of growth stocks like CureVac.

Credit

minimal - The company has a strong balance sheet with low debt, reducing reliance on credit markets.

Live Conditions
Russell 2000 FuturesS&P 500 FuturesDow Jones Futures

Profile

growth - Investors are likely attracted to CureVac for its high revenue growth potential and innovative technology.

high - The stock has shown significant price fluctuations, evidenced by a 23.6% return over the past year but a -14.8% return over the last six months.

Key Metrics to Watch
mRNA vaccine efficacy data from clinical trials
Partnership revenue contributions
Regulatory approval timelines
Research and development spending trends

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.